Advenchen Laboratories Nanjing Ltd.: Clinical Trials

7 trials sponsored by Advenchen Laboratories Nanjing Ltd., newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 unknown, 2 recruiting, 1 completed, 1 not yet recruiting. 6 Phase 1, 1 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 16Unknown 3, Completed 1, Not yet recruiting 1, Recruiting 1
Phase 21Unknown 1
Phase 31Recruiting 1

Follow Advenchen Laboratories Nanjing Ltd.: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers
AL3818 Capsule, Itraconazole capsule, Ticagrelor Tablets - Healthy Volunteer
Phase 1Not yet recruitingAdvenchen Laboratories Nanjing Ltd.162026-03-022026-02-27
A Study of AL8326 in Healthy Subjects
14C-labeled AL8326 - Small Cell Lung Cancer, Solid Tumors
Phase 1CompletedAdvenchen Laboratories Nanjing Ltd.62025-02-212025-08-20
A Phase IIII Study of AL8326 in Small Cell Lung Cancer
AL8326 tablets, placebo - Small Cell Lung Carcinoma
Phase 3RecruitingAdvenchen Laboratories Nanjing Ltd.2432023-10-262024-02-08
A Study of Diet Influence of AL8326 in Chinese Healthy Adult Subjects
AL8326 tablets - Diet, High-Fat, Pharmacokinetics
Phase 1UnknownAdvenchen Laboratories Nanjing Ltd.162022-06-212022-08-03
A Study of AL58805 in Patients With Advanced Tumors
AL58805 - Advanced Tumors
Phase 1RecruitingAdvenchen Laboratories Nanjing Ltd.402020-12-202025-09-17
A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer
AL8326 tablets - Small Cell Lung Cancer
Phase 1 / Phase 2UnknownAdvenchen Laboratories Nanjing Ltd.2372020-10-192021-05-18
A Phase I Study of AL8326 in Advanced Solid Tumor
AL8326 tablets - Advanced Solid Tumors
Phase 1UnknownAdvenchen Laboratories Nanjing Ltd.402017-08-172021-05-18

Conditions studied

Small Cell Lung Carcinoma (3)

Interventions

Itraconazole (1)  ·  Ticagrelor (1)  ·  anlotinib (1)

Countries

China (7)

Top investigators

Dongfang Li (1)  ·  LiYan Miao (1)  ·  Nong Yang (1)  ·  Qing He (1)  ·  Ying Cheng (1)  ·  Yongchang Zhang (1)  ·  Yu Cao (1)